Halozyme Therapeutics, Inc.
HALOHalozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative biologic and drug delivery technologies. They are known for their enzyme-based platforms that enhance the absorption and distribution of therapeutic proteins and peptides, supporting the development of targeted cancer treatments, autoimmune disorders, and other medical conditions. The company's proprietary enzyme, ENHANZE, is used in collaborations with major pharmaceutical companies to improve the efficacy and administration of various biologics.
Company News
Emerging immunotherapy technologies are transforming treatment for gastrointestinal cancers, with companies developing novel combination strategies to activate immune responses in historically resistant tumors. The global cancer immunotherapy market is projected to reach $443.17 billion by 2030.
Renaissance Group initiated a new $35.11 million position in Halozyme Therapeutics, acquiring 478,735 shares representing 1.32% of its U.S. equity assets. The biotech company offers innovative drug delivery technology and has demonstrated strong financial performance with consistent sales growth.
Acumen Pharmaceuticals will report its Q3 2025 financial results on November 12, 2025, hosting a conference call and webcast to provide a business and financial update. The company is developing a novel therapeutic targeting toxic amyloid beta oligomers for Alzheimer's disease treatment.
Pharmaceutical company argenx presented clinical trial data demonstrating VYVGART's effectiveness in treating generalized myasthenia gravis across different patient subtypes, including seronegative patients, with promising results in symptom reduction and steroid use management.
A Phase 1b/2 study of subcutaneous amivantamab in recurrent or metastatic head and neck cancer demonstrated a 45% overall response rate, with rapid and durable tumor responses in patients who had previously progressed on checkpoint inhibitors and chemotherapy.
